10-Q: Nika Pharmaceuticals Reports First Revenue Amidst Restructuring and Expansion Efforts in Q2 2024

Nika Pharmaceuticals reported its first revenue of $156 in Q2 2024, while also undergoing significant restructuring and expansion, including mergers and acquisitions.

Summary

• Nika Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2024, showing a net loss of $54,800, compared to a net loss of $27,806 for the same period in 2023.
• The company recognized its first revenue of $156 from the sale of dietary supplements.
• General and administrative expenses increased to $39,999 from $21,001 year-over-year, primarily due to costs incurred by subsidiaries.
• Professional fees also increased to $14,957 from $6,805 year-over-year, mainly due to legal, audit, and accounting fees.
• The company completed a merger with Nika BioTechnology, Inc., increasing its stake in Nika Europe, Ltd. to 80%.
• Nika Europe, Ltd. is preparing to construct a pharmaceutical factory and has acquired technologies for generic drugs and a dietary supplement.
• The company also acquired 100% of Nika Pharmaceuticals, Ltd., which was later cancelled.
• The company's cash balance decreased to $7,485 from $19,596 at the end of 2023.
• Loans from related parties increased to $530,552 from $57,565 year-over-year.
• The company has an accumulated deficit of $8,956,004 as of June 30, 2024, raising concerns about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a going concern issue, and internal control weaknesses, which overshadow the positive developments like the first revenue and strategic acquisitions. The overall sentiment is negative due to the financial instability and operational challenges.

Positives

• The company recognized its first revenue of $156, marking a milestone in its operational development.
• The merger with Nika BioTechnology, Inc. increased the company's stake in Nika Europe, Ltd. to 80%, providing a stronger foothold in European markets.
• Nika Europe, Ltd. is progressing with the construction of a pharmaceutical factory, which will enhance production capabilities.
• The acquisition of technologies for generic drugs and a dietary supplement expands the company's product portfolio.
• The company secured $530,552 in loans from related parties, providing necessary funding for operations.

Negatives

• The company incurred a net loss of $54,800 for the quarter, an increase from the $27,806 loss in the same period last year.
• General and administrative expenses increased significantly to $39,999, up from $21,001 year-over-year.
• Professional fees also increased to $14,957, compared to $6,805 in the prior year.
• The company's cash balance decreased to $7,485, down from $19,596 at the end of 2023.
• The company has an accumulated deficit of $8,956,004, raising substantial doubt about its ability to continue as a going concern.
• The acquisition of Nika Pharmaceuticals, Ltd. was later cancelled, potentially disrupting strategic plans.

Risks

• The company's accumulated deficit of $8,956,004 raises substantial doubt about its ability to continue as a going concern.
• The company's reliance on loans from related parties for funding may pose a risk to its financial stability.
• The cancellation of the Nika Pharmaceuticals, Ltd. acquisition may impact the company's strategic plans and operations.
• The company's disclosure controls and procedures were deemed not effective for the quarter ended June 30, 2024.
• The company lacks an audit committee and has a lack of separation of duties, which are potential material weaknesses.
• The company's independent accountant resigned, and the company terminated its accounting firm, which may cause delays in financial reporting.

Future Outlook

The company is focused on expanding its operations through its subsidiaries, particularly Nika Europe, Ltd., which is developing a pharmaceutical factory and acquiring new technologies. The company is also working to address its going concern issues and improve its financial position.

Management Comments

• The company is changing its business to focus on the production and distribution of Thymus Nuclear Glycoprotein (TNG) and dietary supplements.
• The company is combining efforts with Immunotech Laboratories BG, Ltd. to realize the registration, production, and distribution of medicinal products based on the Inactivated Pepsin Fraction (IPF) platform.
• The company is working to complete the construction of a pharmaceutical factory in Bulgaria.
• The company is focused on addressing its going concern issues.

Industry Context

The company's focus on pharmaceuticals and dietary supplements aligns with the growing global demand for health and wellness products. The development of a pharmaceutical factory in Europe positions the company to capitalize on the European, Asian, and African markets. The company's strategy of acquiring technologies for generic drugs and dietary supplements is a common approach in the pharmaceutical industry to expand product offerings and market reach.

Comparison to Industry Standards

• Nika Pharmaceuticals is a small company with limited revenue, while many of its competitors are larger and more established.
• The company's net loss and accumulated deficit are significant, indicating financial challenges compared to industry benchmarks.
• The company's reliance on related party loans is not typical for established pharmaceutical companies, which often have access to traditional financing.
• The company's focus on acquiring technologies and building a factory is similar to strategies used by other companies in the pharmaceutical industry to expand their capabilities.
• The company's lack of an audit committee and separation of duties is not in line with best practices for publicly traded companies.

Management Changes

Corporate Governance

Related Party Transactions

• Dimitar Slavchev Savov, CEO, advanced the Company $530,552 and $83,565 during the periods ended June 30, 2024 and December 31, 2023, respectively.
• As of June 30, 2024, the total amount due to Mr. Savov is $632,297.
• The company signed Exclusive Rights Agreements with VITAL and MICAR, both of which are related to Dimitar Slavchev Savov.
• The company signed an Exclusive Rights Agreement with Dimitar Slavchev Savov for the production and sale of dietary supplements.
• Dimitar Slavchev Savov paid for the technologies acquired by Nika Europe, Ltd.
• Dimitar Savov paid the initial down payment for the vial production line equipment.
• Nika Pharmaceuticals, Ltd. made a non-monetary in-kind contribution of a production building and land to the capital of Nika Europe, Ltd., with Dimitar Savov owning 100% of Nika Pharmaceuticals, Ltd.

Stakeholder Impact

• Shareholders may be concerned about the company's financial losses and going concern issues.
• Employees may be affected by the company's restructuring and financial challenges.
• Customers may benefit from the company's expanded product offerings and production capabilities.
• Suppliers may be impacted by the company's financial situation and operational changes.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company is in the process of engaging a new auditor, and a review is expected to be completed by September 30, 2024.
• The company will continue to develop its pharmaceutical factory in Bulgaria.
• The company will continue to work on the production and distribution of its products.
• The company will work to address its going concern issues and improve its financial position.

Key Dates

Keywords

Pharmaceuticals, Merger, Acquisition, Dietary Supplements, Nika Europe, Financial Results, Going Concern, Manufacturing, Generic Drugs, Biotechnology